Stocks / NASDAQ / VYNE Therapeutics Inc.

VYNE Therapeutics Inc.

Our Opinion

VYNE Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of its medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“The data demonstrated that VYNE’s pan-BET inhibitor VYN201 used as an intra-articular injection resulted in significant inhibition of inflammation in a validated animal model of RA1. The data supports the potential to develop VYN201 as a locally-administered intra-articular treatment for an autoimmune joint disease.” Read the following article

Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Company Website: